Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan-Reference-Cited by-同舟云学术

Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan

Published:2020-03-31 Issue:10 Volume:35 Page:1782-1788
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Kitagataya Takashi¹,Suda Goki¹^ORCID,Nagashima Kazunori¹,Katsurada Takehiko¹,Yamamoto Koji¹,Kimura Megumi¹,Maehara Osamu¹,Yamada Ren¹,Shigesawa Taku¹,Suzuki Kazuharu¹,Nakamura Akihisa¹,Ohara Masatsugu¹,Umemura Machiko¹,Kawagishi Naoki¹^ORCID,Nakai Masato¹,Sho Takuya¹,Natsuizaka Mitsuteru¹,Morikawa Kenichi¹^ORCID,Ogawa Koji¹,Ohnishi Shunsuke¹^ORCID,Komatsu Yoshito²,Hata Hiroo³,Takeuchi Satoshi⁴,Abe Takashige⁵,Sakakibara‐Konishi Jun⁶,Teshima Takanori⁷,Homma Akihiro⁸,Sakamoto Naoya¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan

2. Department of Cancer Chemotherapy Hokkaido University Hospital Cancer Center Sapporo Japan

3. Department of Dermatology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

4. Department of Medical Oncology, Graduate School of Medicine Hokkaido University Sapporo Japan

5. Departments of Urology Hokkaido University Hospital Sapporo Japan

6. Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

7. Department of Hematology, Faculty of Medicine, Graduate School of Medicine Hokkaido University Sapporo Japan

8. Department of Otolaryngology – Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

Funder

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15041

Reference26 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

3. Nivolumab in renal cell carcinoma: latest evidence and clinical potential

4. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

5. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case Report of Pembrolizumab-Induced Allergic Hepatitis;Cureus;2024-07-16

2. Immunotherapy-induced hepatitis in metastatic colorectal cancer: a systematic review and meta-analysis;Baylor University Medical Center Proceedings;2024-07-08

3. Diagnostic guide for immune checkpoint inhibitor‐induced liver injury;Hepatology Research;2024-06-17

4. Guide for the Diagnosis of Immune Checkpoint Inhibitor-Induced Liver Injury;Kanzo;2024-06-01

5. Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy;Diagnostics;2024-04-14